Angelo Porciuncula

Angelo Porciuncula is an Associate Research Scientist in the Department of Pathology at Yale School of Medicine, affiliated with the Schalper Lab. He holds a PhD from the University of Navarra. His research focuses on immunology, cancer therapy, and stem cell biology, with a particular emphasis on immune microenvironment modulation in oncology and translational drug development. Key projects include studying STING pathway activation via antibody-drug conjugates (e.g., TAK-500) targeting CCR2-expressing myeloid cells, as well as investigating immunotherapeutic biomarkers in lung cancer and glioblastoma.

His work spans clinical-stage drug evaluation, tumor immunology, and epigenetic reprogramming of stem cells. Publications highlight contributions to understanding senescence mechanisms in cancer, pancreatic differentiation of iPSCs, and the role of OX40/OX40L pathways in tumor immunity.

Porciuncula collaborates widely, including with Kurt Schalper and teams at Takeda Pharmaceuticals. His research bridges basic science and clinical applications, aiming to advance targeted therapies and regenerative medicine strategies.